217 related articles for article (PubMed ID: 32186422)
1. Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients.
Guolo F; Minetto P; Clavio M; Marcolin R; Miglino M; Passannante M; Caviglia F; Ballerini F; Tedone E; Kunkl A; Mangerini R; Contini P; Colombo N; Cagnetta A; Cea M; Carminati E; Pugliese G; Gobbi M; Lemoli RM
Leuk Lymphoma; 2020 Jul; 61(7):1695-1701. PubMed ID: 32186422
[TBL] [Abstract][Full Text] [Related]
2. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
[TBL] [Abstract][Full Text] [Related]
3. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the
Soare DS; Radu E; Dumitru I; Vlădăreanu AM; Bumbea H
Leuk Lymphoma; 2021 Nov; 62(11):2716-2726. PubMed ID: 34034609
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm.
Wang W; Xu J; Khoury JD; Pemmaraju N; Fang H; Miranda RN; Yin CC; Hussein SE; Jia F; Tang Z; Hu S; Konopleva M; Medeiros LJ; Wang SA
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884435
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Diagnosis of Acute Myeloid Leukemia with CD56-Blastic Plasmacytoid Dendritic Cell Neoplasm.
Zhang X; Wu Y; Li C; Shen K; Li R
Clin Lab; 2023 Jun; 69(6):. PubMed ID: 37307129
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
9. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
11. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
12. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
13. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
[TBL] [Abstract][Full Text] [Related]
14. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
[TBL] [Abstract][Full Text] [Related]
15. Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation.
Hamadeh F; Awadallah A; Meyerson HJ; Beck RC
Cytometry B Clin Cytom; 2020 Jan; 98(1):43-51. PubMed ID: 30614203
[TBL] [Abstract][Full Text] [Related]
16. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
17. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
Tiribelli M; Raspadori D; Geromin A; Cavallin M; Sirianni S; Simeone E; Bocchia M; Fanin R; Damiani D
Leuk Res; 2017 Jul; 58():31-38. PubMed ID: 28407515
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
Schmid C; Labopin M; Socié G; Daguindau E; Volin L; Huynh A; Bourhis JH; Milpied N; Cornelissen J; Chevallier P; Maertens J; Jindra P; Blaise D; Lenhoff S; Ifrah N; Baron F; Ciceri F; Gorin C; Savani B; Giebel S; Polge E; Esteve J; Nagler A; Mohty M;
Blood; 2015 Oct; 126(17):2062-9. PubMed ID: 26351297
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic abnormalities in
Fu W; Huang A; Xu L; Peng Y; Gao L; Chen L; Chen J; Tang G; Yang J; Ni X
Leuk Lymphoma; 2022 Aug; 63(8):1956-1963. PubMed ID: 35227153
[No Abstract] [Full Text] [Related]
20. [Immunohistochemical evaluation of BCL-2 expression in acute myeloid leukemia, myeloid sarcoma, and blastic plasmacytoid dendritic cell neoplasm].
Saika W; Kawahara M; Tashiro H; Teramoto Y; Nagai S; Kumode M; Iwasa M; Asai A; Fujishiro A; Nishimura R; Minamiguchi H; Moritani S; Kito K; Andoh A
Rinsho Ketsueki; 2020; 61(12):1647-1653. PubMed ID: 33441515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]